LB Pharmaceuticals (LBRX) closed at $42.01 on November 6, 2026, up 10.3% from the previous close, on volume of 456,085 shares (30-day average 408,524).
Data as of November 6, 2026.
6-Nov-2026
TipRanks (Fri, 6-Nov 2:56 PM ET)
Wall Street Analysts Are Neutral on Top NA Picks
TipRanks (Fri, 6-Nov 9:21 AM ET)
TipRanks (Fri, 6-Nov 9:10 AM ET)
LB Pharmaceuticals GAAP EPS of -$1.79
Seeking Alpha News (Fri, 6-Nov 3:42 AM ET)
LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 5-Nov 4:05 PM ET)
LB Pharmaceuticals to Participate in Upcoming Investor Events
Globe Newswire (Thu, 15-Oct 4:05 PM ET)
LB Pharmaceuticals issues 400,000-option inducement grants as new CMO and CFO join
Market Chameleon (Mon, 12-Oct 7:30 AM ET)
Globe Newswire (Sat, 10-Oct 8:00 AM ET)
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 9-Oct 4:42 PM ET)
Globe Newswire (Tue, 6-Oct 8:00 AM ET)
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
LB Pharmaceuticals trades on the NASDAQ stock market under the symbol LBRX.
As of November 6, 2026, LBRX stock price climbed to $42.01 with 456,085 million shares trading.
LBRX has a beta of 1.36, meaning it tends to be more sensitive to market movements. LBRX has a correlation of 0.10 to the broad based SPY ETF.
LBRX has a market cap of $1.36 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that LBRX belongs to (by Net Assets): VTI, IWM, VXF, XPH, SCHA.
LBRX has outperformed the market in the last year with a price return of +170.9% while the SPY ETF gained +10.8%. However, in the short term, LBRX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -12.8% vs -4.1% return in SPY. But in the last 2 weeks, LBRX shares have fared better than the market returning +8.5% compared to SPY -3.2%.
LBRX support price is $36.51 and resistance is $39.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LBRX shares will trade within this expected range on the day.
